Eli Lilly's Q1 revenue surged 56%, GLP-1 drug sales nearly doubled, annual guidance raised | Earnings Report
```
Eli Lilly delivered a first-quarter performance that far exceeded market expectations thanks to the strong performance of its GLP-1 weight loss and diabetes drugs, immediately raising its full-year guidance, with pre-market share price surging over 5%.
Lilly’s total revenue for the first quarter reached $19.8 billion, up 56%